Study on the correlation between combined detection of RACK1, M2/M1in oral squamous cell carcinoma, prognosis of the patients

doi:10.19439/j.sjos.2022.05.013

Abstract

Abstract: PURPOSE: To explore the relationship between combined detection of tissue active protein kinase C receptor 1 (RACK1) and M2/M1 and the prognosis of oral squamous cell carcinoma (OSCC). METHODS: 129 OSCC patients admitted to the Affiliated Hospital of Nantong University were selected as the research subjects from February 2017 to May 2018. RACK1 and M2/M1 in cancer tissues and adjacent tissues of patients were detected and compared. The relationship between RACK1 expression, M2/M1 and clinicopathological factors, and relationship between RACK1 expression, M2/M1 and prognosis in cancer tissue were analyzed. SPSS 18.0 software package was used for data analysis. RESULTS: The positive expression rate of RACK1 and the value of M2/M1 in cancer tissues were significantly higher than those in adjacent tissues (P<0.05). The positive expression rate of RACK1 in cancer tissues of patients with stage Ⅲ-Ⅳ, cervical lymph node metastasis, and vascular involvement were significantly higher than those with stage Ⅰ-Ⅱ, no lymph node metastasis, and no vascular involvement(P<0.05). M2/M1 values in cancer tissues of patients with stage Ⅲ-Ⅳ, poor differentiation, and cervical lymph node metastasis were significantly higher than those with stage Ⅰ-Ⅱ, moderate differentiation, and no cervical lymph node metastasis(P<0.05). Cox regression analysis showed that the stage of tumor, cervical lymph node metastasis, positive expression rate of RACK1, and M2/M1 were independent prognostic factors affecting overall survival (P<0.05). ROC curve showed that AUC of cancer tissue RACK1, M2/M1 and combination of the two to predict the prognosis of OSCC patients were 0.743, 0.718 and 0.875, respectively. The survival rate of patients with positive expression of RACK1 was 62.24%, and the survival rate of patients with negative expression of RACK1 was 92.31%. The overall survival rate of patients with positive expression of RACK1 and patients with negative expression were compared, and the difference was statistically significant(P<0.05). The survival rate of patients with M2/M1≥2.06 was 61.70%, the survival rate of patients with M2/M1<2.06 was 88.24%, and the overall survival curve of patients with M2/M1≥2.06 was compared with that of patients with M2/M1<2.06, and the difference was statistically significant(P<0.05). CONCLUSIONS: The expression of RACK1 and M2/M1 is abnormally high in cancer tissues of OSCC patients. The expression of RACK1 and M2/M1 is related to the patient's pathology and prognosis. The combination of the two has certain efficacy in predicting the prognosis of OSCC patients.

Key words: Oral cavity, Squamous cell carcinoma, Active protein kinase C receptor 1, M2 type macrophages, M1 type macrophages, Prognosis

CLC Number:

R739.8

ZHU Jiang, XU Teng, SONG Dong-hui, WU Sen-bin. Study on the correlation between combined detection of RACK1, M2/M1in oral squamous cell carcinoma, prognosis of the patients[J]. Shanghai Journal of Stomatology, 2022, 31(5): 517-522.

References

[1] Hema Shree K, Ramani P, Sherlin H, et al.Saliva as a diagnostic tool in oral squamous cell carcinoma-a systematic review with meta analysis[J]. Pathol Oncol Res, 2019, 25(2): 447-453.
[2] Sun LP, Xu K, Cui J, et al.Cancer-associated fibroblast-derived exosomal miR-382-5p promotes the migration and invasion of oral squamous cell carcinoma[J]. Oncol Rep, 2019, 42(4): 1319-1328.
[3] Yu Z, Jiang X, Qin L, et al.A novel UBE2T inhibitor suppresses Wnt/β-catenin signaling hyperactivation and gastric cancer progression by blocking RACK1 ubiquitination[J]. Oncogene, 2021, 40(5): 1027-1042.
[4] Fadhil M, Abdul-Rasheed O, Al-Naqqash M.Clinical value of peripheral blood M2/M1 like monocyte ratio in the diagnosis of breast cancer and the differentiation between benign and malignant breast tumors[J]. Acta Biochim Pol, 2019, 66(4): 437-443.
[5] Lin H, Zhang X, Liao L, et al.CPNE3 promotes migration and invasion in non-small cell lung cancer by interacting with RACK1 via FAK signaling activation[J]. J Cancer, 2018, 9(22): 4215-4222.
[6] 周小庆, 金丹. 子宫颈癌组织中RACK1和β-catenin的表达及临床意义[J]. 临床与实验病理学杂志, 2019, 35(1): 60-64.
[7] Oya Y, Hayakawa Y, Koike K.Tumor microenvironment in gastric cancers[J]. Cancer Sci, 2020, 111(8): 2696-2707.
[8] Mehla K, Singh PK.Metabolic regulation of macrophage polarization in cancer[J]. Trends Cancer, 2019, 5(12): 822-834.
[9] Weber M, Wehrhan F, Baran C, et al.Malignant transformation of oral leukoplakia is associated with macrophage polarization[J]. J Transl Med, 2020, 18(1): 11-14.
[10] 中华口腔医学会口腔颌面外科专业委员会肿瘤学组. 口腔颌面部恶性肿瘤治疗指南[J]. 中国口腔颌面外科杂志, 2010, 3(7): 395-403.
[11] Córdova LA, Loi F, Lin TH, et al.CCL2, CCL5, and IGF-1 participate in the immunomodulation of osteogenesis during M1/M2 transition in vitro[J]. J Biomed Mater Res A, 2017, 105(11): 3069-3076.
[12] Johnson AG, Lapointe CP, Wang J, et al.RACK1 on and off the ribosome[J]. RNA, 2019, 25(7): 881-895.
[13] Park JH, Jeong E, Lin J, et al.RACK1 interaction with c-Src is essential for osteoclast function[J]. Exp Mol Med, 2019, 51(7): 1-9.
[14] Wu MF, Lin CA, Yuan TH, et al.The M1/M2 spectrum and plasticity of malignant pleural effusion-macrophage in advanced lung cancer[J]. Cancer Immunol Immunother, 2021, 70(5): 1435-1450.
[15] 周洋, 刘晓军, 孙昊, 等. 宫颈癌中活化的蛋白激酶C受体1,低氧诱导因子1α与血管内皮生长因子的表达及病理学意义[J]. 第二军医大学学报, 2019, 40(10): 1078-1082.
[16] Buoso E, Masi M, Racchi M, et al.Endocrine-disrupting chemicals' (EDCs) effects on tumour microenvironment and cancer progression: emerging contribution of RACK1[J]. Int J Mol Sci, 2020, 21(23): 9229-9232.
[17] Lee YS, Song SJ, Hong HK, et al.The FBW7-MCL-1 axis is key in M1 and M2 macrophage-related colon cancer cell progression: validating the immunotherapeutic value of targeting PI3Kγ[J]. Exp Mol Med, 2020, 52(5):815-831.
[18] Dan H, Liu S, Liu J, et al.RACK1 promotes cancer progression by increasing the M2/M1 macrophage ratio via the NF-κB pathway in oral squamous cell carcinoma[J]. Mol Oncol, 2020, 14(4): 795-807.